The promise and potential pitfalls of chimeric antigen receptors
- 25 March 2009
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Immunology
- Vol. 21 (2), 215-223
- https://doi.org/10.1016/j.coi.2009.02.009
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBlood, 2007
- Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia XenograftsClinical Cancer Research, 2007
- Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T‐cellsThe Prostate, 2007
- T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cellsBlood, 2006
- CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor EnhancesIn vivoPersistence and Antitumor Efficacy of Adoptively Transferred T CellsCancer Research, 2006
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005
- Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytesGene Therapy, 2003
- The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysCell, 1991